PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Plasma Protease C1-inhibitor Treatment Market – Drivers

The increasing focus of biopharmaceutical companies on development of effective plasma protease C1-inhibitor treatment drugs/therapy treating various health conditions such as HAE, diabetic macular edema (DME), and others, is expected to drive growth of the plasma protease C1-inhibitor treatment market. Several kallikrein inhibitor therapies are currently in preclinical and clinical development stages. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME). Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).

• Increasing product approvals/ launches
• Increasing research and development
• Adoption of inorganic strategies

Global Plasma Protease C1-inhibitor Treatment Market - Restraints

However, the rare occurrence of the HAE makes it difficult for efficient diagnosis and opting alternative therapies to control the disease are the major factors that are expected to restrain the plasma protease c1-inhibitor treatment market growth over the forecast period.

Figure 2. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Region, 2020

• The rare occurrence of the HAE
• Lower diagnosis rate